Validation of serum biomarkers for detection of early- and late-stage endometrial cancer

Farias-Eisner, Gina; Su, Feng; Robbins, Terry; Kotlerman, Jenny; Reddy, Srinivasa T.; Farias‐Eisner, Robin

doi:10.1016/j.ajog.2009.07.049

Cited by 43 publications

(38 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The implication of TTR in the formation of amyloid deposits in familial amyloidosis and senile systemic amyloidosis has been shown previously (22,23). In addition, a number of studies have shown the potential value of serum TTR in cancer diagnosis, including ovarian (21,24), endometrial (25) and lung cancer (14)(15)(16).…”

Section: Introductionmentioning

confidence: 89%

“…As a well-known negative acute-phase protein, a decreased serum concentration of TTR has been reported in cases of severe liver disease, malnutrition and acute inflammation. In addition, TTR was found to decrease in the sera of patients with ovarian and endometrial cancers (24,25), and the mechanisms it is involved in remain unknown. Elevated levels of TTR were detected in the aqueous humor of patients with primary open-angle glaucoma and were considered to play a role in the onset of glaucoma (28).…”

Section: Serum Pleural Effusion -------------------------------------mentioning

confidence: 99%

See 1 more Smart Citation

Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection

et al. 2014

View full text Add to dashboard Cite

Abstract. Satisfactory biomarkers for screening and early diagnosis of lung cancer remain scarce and require further investigation. The aim of the present study was to examine the changes of the biochemical and protein composition in the serum and pleural effusion from lung cancer and lung infection (bacterial pneumonia) patients. A total of 92 patients with lung cancer, 38 with bacterial pneumonia and 42 healthy controls were enrolled in the study. The serum levels of cholesterol, apolipoprotein A and transthyretin (TTR) in the lung cancer patients were higher than that of the lung infection patients (P<0.05). The levels of TTR were higher, whereas the activity of adenosine deaminase (ADA) was lower in the pleural effusion from the lung cancer patients compared to the lung infection patients (P<0.05). Furthermore, the pleural effusion/serum TTR ratios in the lung cancer patients were higher, whereas the ratios of ADA were lower (P<0.05). By matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis, four major peaks corresponding to native TTR, Sul-TTR, Cys-TTR and Cysgly-TTR were observed in the serum of the lung cancer and lung infection patients. A significant increase was found in the proportion of Cysgly-TTR in the pleural effusion from the patients with lung cancer. The data indicated that a combination of pleural effusion/serum TTR ratios and modified TTR may be beneficial for the differential diagnosis between lung cancer and lung infection. IntroductionLung cancer is one of the most common malignant tumors worldwide, with a 5-year survival rate of 14% (1). Thus far, the statistics for cancer occurrence and outcome show that lung cancer remains a primary cause of mortality from cancer (2,3). Since the incidence and mortality of lung cancer increases significantly every year, it represents a major economic burden to society. Currently, the screening and early diagnosis of lung cancer in clinics relies mainly on magnetic resonance imaging (MRI) and computed tomography (CT) imaging, whereas the final diagnosis is established on the basis of histopathological examination results. The early clinical manifestations of lung cancer patients are relatively mild and not typical, easily overlooked or confused with benign inflammatory disease, such as lung infection. Therefore, early identification and diagnosis of lung cancer is significant since lung cancer may be curable in its early stages (1).Thus far, increasing attention has focused on searching for improved biomarkers that function not only to detect lung cancer at an early stage but also to explore the molecular mechanisms that underlie cancer development. Tumor markers, including carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCAg) and cytokeratin-19 fragments (Cyfra21-1), are clinically applied for the early detection of lung cancer (4,5). However, the sensitivity and specificity of these biomarkers are not adequate (6-8). Combined detection usi...

show abstract

Section: Introductionmentioning

confidence: 89%

Section: Serum Pleural Effusion -------------------------------------mentioning

confidence: 99%

Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection

et al. 2014

View full text Add to dashboard Cite

show abstract

“…These abilities reveal the importance of the identification of biomarkers in detecting premalignant or early-stage malignant cancer [11]. Currently, there are no wellestablished biomarkers in clinical use for EC [78]. Cancer antigen 125 (CA-125) has been the traditional biomarker used in clinical practice to monitor individuals with EC; however, this biomarker has limited ability to monitor disease in its earliest stages, monitor therapy and determine recurrence [79].…”

Section: Novel Biomarkers That Have Been Investigated In the Field Of Ecmentioning

confidence: 99%

Advancements in the Use of Blood Tests for Cancer Screening in Women at High Risk for Endometrial and Breast Cancer

Ambeba

Linkov

2011

Future Oncol.

View full text Add to dashboard Cite

Several years ago, it was argued that the identification of serum biomarkers is one of the most promising approaches for the detection of early-stage malignant or even premalignant lesions. In this review, the need to establish better monitoring protocols is described for obese women who are at higher risk for the development of malignancies commonly associated with excess weight; specifically endometrial and postmenopausal breast cancer. These cancers have been chosen for this review article as our aim was to focus on female cancers that have been linked with obesity. Cancer screening is essential in detecting disease in its earliest stage in order to reduce morbidity and mortality; however, effective screening is not available for many cancer types. Even for cancers that have effective screening protocols available, there are barriers to screening in obese individuals, such as reduced mobility and embarrassment. These barriers often delay screening in these vulnerable population groups, leading to detection of the disease at a more advanced stage and ultimately leading to a poorer prognosis. As of today, biomarkers do not replace but augment imaging and other existing screening approaches. Future development of blood- or urine-based biomarkers as a way to screen individuals at high risk for certain cancers may prove to be an excellent method for overcoming the barriers that individuals at high risk are facing today. The overall purpose of this manuscript is to provide an overview of screening techniques and to identified barriers and alternate biomarker-based approaches for improvement of endometrial and breast cancer screening in obese women.

show abstract

“…The ideal tumor marker needs to have high sensitivity and specificity for the distinction of patients with cancers and benign diseases as well as healthy controls [3]. Serum CA 125 is suitable for the diagnosis of advanced phase ovarian cancers, but there are no reliable serum biomarkers that can be clinically used for the diagnosis of endometrial cancer [4].…”

Section: Introductionmentioning

confidence: 99%

Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation

Yılmaz

Kumtepe

2017

Eurasian J Med

View full text Add to dashboard Cite

Objective: Currently, no clinically useful tumor marker is available for primary diagnosis in endometrial cancer. Human epididymis protein-4 (HE-4) has high sensitivity and specificity as a tumor marker. Further, HE-4 has been shown to be elevated in early stage endometrial cancer and is more sensitive than CA 125. In our study, CA 125 and HE-4 reputation as a tumor marker for diagnosis of ovarian and endometrial cancer with the use of both the availability and affect the way we investigated the rate of diagnosis. Materials and Methods:Here 20 patients with ovarian cancer, 26 patients with endometrial cancer, which had been histologically diagnosed, and 40 healthy volunteers were included. Peripheral blood samples were taken and serum CA 125 and HE-4 were tested.Results: Serum CA 125 and HE-4 levels in patients with ovarian cancer were found to be significantly higher than those in healthy volunteers (p<0.05). Receiver-operating characteristic (ROC) analysis was performed. For patients with ovarian cancer and healthy controls, the CA 125 (0.83) and HE-4 (0.84) levels showed increased sensitivity (95%). There was no significant difference in the CA 125 levels in patients with endometrial cancer and healthy controls (p>0.05), whereas HE-4 levels were found to be higher in patients with endometrial cancer than in healthy controls (p<0.05). ROC analysis was performed. For endometrial cancer patients and healthy controls, the CA 125 (0.59) and HE-4 (0.63) levels showed increased sensitivity (88.5%). Conclusion:In ovarian and endometrial cancer, wherein early diagnosis is the most important factor for prognosis and survival, HE-4 is a new serum tumor marker that can be used with the aim of noninvasive diagnoses. For early diagnosis, the concomitant use of CA 125 and HE-4 is more effective and reliable than using either of them alone.Keywords: Ovary, endometrium, cancer, diagnosis, tumor marker ÖZ Amaç: CA 125 erken evre over kanserlerinin sadece %50'sinde yükselir. Endometrium kanserinde klinik pratikte rutin olarak kullanılan tümör marker yoktur. Human epididimis protein-4 (HE-4) over kanserlerinde yüksek sensitivite ve spesifiteye sahiptir. Endometrial kanserde CA 125 den daha sensitif olduğu ve erken evrede yükseldiği gösterilmiştir. Çalışmamızda CA 125 ve HE-4'ün over ve endometrium kanserinde tümör markerı olarak kullanılabilirliğini ve ikisinin birlikte kullanımın teşhis oranını ne şekilde etkileyeceğini araştırdık.Gereç ve Yöntem: Çalışmamıza histopatolojik olarak tanısı konulan 20 over kanseri, 26 endometrium kanseri hasta ile jinekolojik problemi olmayan 40 sağlıklı gönüllü dahil edilmiştir. MR görüntülemesiyle FIGO sistemine göre evreleri belirlendi. Hastalardan preoperatif olarak ve sağlıklı gönüllülerden periferik kan alınarak serum CA 125 ve HE-4 düzeyleri çalışıldı.Bulgular: Over kanseri hastalarının serum CA 125 ve HE-4 düzeyleri sağlıklı kontrollerinkinden anlamlı yüksek bulundu (p<0,05). ROC (Receiver Operatör Characteristic) analizi uygulandığında over kanseri hastalarında CA 125 (0,83) ve HE...

show abstract

Validation of serum biomarkers for detection of early- and late-stage endometrial cancer

Cited by 43 publications

References 25 publications

Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection

Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection

Advancements in the Use of Blood Tests for Cancer Screening in Women at High Risk for Endometrial and Breast Cancer

Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation

Contact Info

Product

Resources

About